151 related articles for article (PubMed ID: 27509004)
1. 1,2,3-Triazoles as Amide Bioisosteres: Discovery of a New Class of Potent HIV-1 Vif Antagonists.
Mohammed I; Kummetha IR; Singh G; Sharova N; Lichinchi G; Dang J; Stevenson M; Rana TM
J Med Chem; 2016 Aug; 59(16):7677-82. PubMed ID: 27509004
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication.
Ali A; Wang J; Nathans RS; Cao H; Sharova N; Stevenson M; Rana TM
ChemMedChem; 2012 Jul; 7(7):1217-29. PubMed ID: 22555953
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of indole derivatives as Vif inhibitors.
Pu C; Luo RH; Zhang M; Hou X; Yan G; Luo J; Zheng YT; Li R
Bioorg Med Chem Lett; 2017 Sep; 27(17):4150-4155. PubMed ID: 28754362
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biological evaluation and molecular docking study of N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif antagonists.
Zhou M; Luo RH; Hou XY; Wang RR; Yan GY; Chen H; Zhang RH; Shi JY; Zheng YT; Li R; Wei YQ
Eur J Med Chem; 2017 Mar; 129():310-324. PubMed ID: 28235704
[TBL] [Abstract][Full Text] [Related]
5. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.
Zhang S; Zhong L; Chen B; Pan T; Zhang X; Liang L; Li Q; Zhang Z; Chen H; Zhou J; Luo H; Zhang H; Bai C
Antiviral Res; 2015 Oct; 122():20-7. PubMed ID: 26241003
[TBL] [Abstract][Full Text] [Related]
6. Viral infectivity factor: a novel therapeutic strategy to block HIV-1 replication.
Yang G; Xiong X
Mini Rev Med Chem; 2013 Jun; 13(7):1047-55. PubMed ID: 23621690
[TBL] [Abstract][Full Text] [Related]
7. Lead optimization to improve the antiviral potency of 2-aminobenzamide derivatives targeting HIV-1 Vif-A3G axis.
Zhong X; Luo R; Yan G; Ran K; Shan H; Yang J; Liu Y; Yu S; Pu C; Zheng Y; Li R
Eur J Med Chem; 2021 Nov; 224():113680. PubMed ID: 34245947
[TBL] [Abstract][Full Text] [Related]
8. Indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors.
Huang W; Zuo T; Luo X; Jin H; Liu Z; Yang Z; Yu X; Zhang L; Zhang L
Chem Biol Drug Des; 2013 Jun; 81(6):730-41. PubMed ID: 23405965
[TBL] [Abstract][Full Text] [Related]
9. [Research methods of anti-HIV-1 inhibitors targeting at Vif-APOBEC3G axis].
Qiao X; Zhang W; Li Z; Zeng Y
Zhongguo Zhong Yao Za Zhi; 2011 Mar; 36(6):806-9. PubMed ID: 21710755
[TBL] [Abstract][Full Text] [Related]
10. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
11. An in silico approach for identification of novel inhibitors as a potential therapeutics targeting HIV-1 viral infectivity factor.
Sinha C; Nischal A; Bandaru S; Kasera P; Rajput A; Nayarisseri A; Khattri S
Curr Top Med Chem; 2015; 15(1):65-72. PubMed ID: 25579575
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of 2-amino-N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif inhibitors.
Zhang RH; Wang S; Luo RH; Zhou M; Zhang H; Xu GB; Zhao YL; Li YJ; Wang YL; Yan G; Liao SG; Zheng YT; Li R
Bioorg Med Chem Lett; 2019 Dec; 29(24):126638. PubMed ID: 31685340
[TBL] [Abstract][Full Text] [Related]
13. [Progress in the study of HIV-1 Vif and related inhibitors].
Li ZY; Zhan P; Liu XY
Yao Xue Xue Bao; 2010 Jun; 45(6):684-93. PubMed ID: 20939174
[TBL] [Abstract][Full Text] [Related]
14. An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G.
Ejima T; Hirota M; Mizukami T; Otsuka M; Fujita M
Int J Mol Med; 2011 Oct; 28(4):613-6. PubMed ID: 21725586
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel and potent class of anti-HIV-1 maturation inhibitors with improved virology profile against gag polymorphisms.
Tang J; Jones SA; Jeffrey JL; Miranda SR; Galardi CM; Irlbeck DM; Brown KW; McDanal CB; Johns BA
Bioorg Med Chem Lett; 2017 Jun; 27(12):2689-2694. PubMed ID: 28454672
[TBL] [Abstract][Full Text] [Related]
16. ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction.
Miyakawa K; Matsunaga S; Kanou K; Matsuzawa A; Morishita R; Kudoh A; Shindo K; Yokoyama M; Sato H; Kimura H; Tamura T; Yamamoto N; Ichijo H; Takaori-Kondo A; Ryo A
Nat Commun; 2015 Apr; 6():6945. PubMed ID: 25901786
[TBL] [Abstract][Full Text] [Related]
17. Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
Kirschberg TA; Balakrishnan M; Huang W; Hluhanich R; Kutty N; Liclican AC; McColl DJ; Squires NH; Lansdon EB
Bioorg Med Chem Lett; 2008 Feb; 18(3):1131-4. PubMed ID: 18083512
[TBL] [Abstract][Full Text] [Related]
18. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
[TBL] [Abstract][Full Text] [Related]
19. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
20. Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.
Rashad AA; Acharya K; Haftl A; Aneja R; Dick A; Holmes AP; Chaiken I
Org Biomol Chem; 2017 Sep; 15(37):7770-7782. PubMed ID: 28770939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
